This research is Trending!
June 7, 2026JAMA
Finerenone in Patients With Chronic Kidney Disease Due to Glomerular Diseases
Authors
Discussion
Loading...
Member takes
Implication
Randomized trial evaluates finerenone's effects on kidney function in patients with glomerular diseases, suggesting potential benefits.
Key Points
- To evaluate the efficacy and safety of finerenone in patients with chronic kidney disease due to glomerular diseases.
- Prespecified exploratory subgroup analysis of a randomized, double-blind, placebo-controlled trial
- Involved adults with nondiabetic chronic kidney disease and specific eGFR and urinary albumin to creatinine ratios
- Participants received either finerenone (10 mg or 20 mg daily) or placebo.
- Total eGFR decline was -3.50 mL/min/1.73 m2 per year with finerenone compared to -4.23 with placebo (difference 0.73; 95% CI, 0.22-1.24)
- Finerenone reduced albuminuria by 42% after 12 months (95% CI, 35%-48%)
- Reduced the risk of kidney failure or 40% eGFR decline (7.42 vs 9.60 events per 100 patient-years; HR 0.74; 95% CI, 0.57-0.97)
Cite This Study
Neuen et al. (2026) studied this question.